Effect of an inhaled alpha4-antagonist on the allergen-induced late asthmatic response in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 135s Year: 2005
R411 treatment reduces asthma exacerbations and attenuates FEV1 fall following steroid withdrawal in moderate asthma Source: Eur Respir J 2005; 26: Suppl. 49, 252s Year: 2005
Effects of regular formoterol treatment on airway hyperresponsiveness in patients with mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Short-term treatment with sistemic corticosteroids blunted neutrophilic airway response to ozone in mild asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 569s Year: 2002
Bronchodilator response following methacholine-induced bronchoconstriction predicts acute asthma exacerbations Source: Eur Respir J 2016; 48: 104-114 Year: 2016
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
IPL576,092 reduces allergen-induced late asthmatic responses, sputum eosinophilia and airway hyperresponsiveness in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 104s Year: 2003
Tolerance to the protective effect of salmeterol on allergen challenge in mild untreated asthmatics and in moderate asthmatics on inhaled corticosteroid treatment Source: Eur Respir J 2001; 18: Suppl. 33, 103s Year: 2001
Effects of eotaxin inhalation in patients with mild asthma Source: Eur Respir J 2002; 20: Suppl. 38, 112s Year: 2002
Evaluation of the bronchoprotective effects of salmetrol HFA and salmetrol CFC in adult patients with chronic stable mild to moderate asthma Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009
Oral montelukast in patients with acute severe asthma Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
Bronchodilator effect of deep inhalation, airway inflammation, and allergen avoidance in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 383s Year: 2003
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Airway inflammation affects the perception of bronchoconstriction in asthma but not in CAO patients Source: Eur Respir J 2003; 22: Suppl. 45, 417s Year: 2003
Effects of salmeterol, formoterol and placebo on pulmonary function and symptom recovery after histamine provocation in mild asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 710s Year: 2004
Formoterol restores corticosteroid responses in corticosteroid-insensitive severe asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Mepolizumab improves small airway function in severe eosinophilic asthma Source: International Congress 2018 – The value of lung function testing in various pathophysiological conditions Year: 2018
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009